BROOMFIELD, CO , May 14, 2019 (GLOBE NEWSWIRE) — Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that results from the company’s international, single-arm, open-label early feasibility study (EFS) of the Colibri transcatheter aortic valve implantation (TAVI) system will be presented at the upcoming EuroPCR annual […]
Coronary/Structural Heart
Cordis Continues to Expand Interventional Cardiology Portfolio with Radial Offering
DUBLIN, Ohio, May 14, 2019 /PRNewswire/ — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures. The transradial approach uses the radial artery in the wrist to access the body’s […]
Quantum Genomics Announces the Publication of a New Scientific Article in the Journal Hypertension
PARIS and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of a new scientific article in the […]
Spacelabs Debuts Sentinel 11 With Enhanced Patient Data Security and Accessibility for Cardiologists
SNOQUALMIE, Wash.–(BUSINESS WIRE)–Spacelabs Healthcare® (the “Company” or “Spacelabs”) debuted Sentinel® 11 at the 40th Annual Heart Rhythm Scientific Sessions in San Francisco. This latest release from Spacelabs advances cardiology information management with optimized workflows, expanded connectivity, and robust data security capabilities. “As healthcare organizations face increasingly sophisticated cybersecurity threats, the […]
MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) — MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced the award of $750,000 divided among three innovative research projects through the first cycle of its MyoSeeds™ Research Grants Program (“MyoSeeds”). MyoSeeds is […]
ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations
ANAHEIM, Calif.–(BUSINESS WIRE)–ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results of its PleuraFlow® device were presented at the American Association for Thoracic Surgery (AATS) 99th Annual meeting on May 4 in Toronto, Canada. This new data stems from a trial evaluating the use of ClearFlow’s […]
Pi-Cardia Successfully Completes First-in-Human Studies with Novel Non-implant Based Treatment of Aortic Stenosis
REHOVOT, Israel, May 7, 2019 /PRNewswire/ — Pi-Cardia Ltd. (www.pi-cardia.net), announced today that it successfully completed the First-in-Human (FIH) studies with its Leaflex™ Performer catheter. The Leaflex™ Performer is a trans-femoral catheter that uses two unique mechanical structures for scoring valve calcification at multiple locations. These scoring lines create separation between the calcium […]
Corindus Equips the World’s First Fully Robotic Catheterization Laboratory
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Vascular Robotic Systems, making it the first hospital […]
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin‑mediated amyloidosis
SILVER SPRING, Md., May 6, 2019 /PRNewswire/ — On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin‑mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the […]
Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™
VANCOUVER, May 6, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that 1,000 patients diagnosed with refractory angina have been […]



